HCV genotype
Performance Comparison of the Versant HCV Genotype 2 0 Assay (LiPA) and the Abbott Realtime HCV Genotype II Assay for Detecting Hepatitis C Virus Genotype 6
8
Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test
5
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
7
Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO LiPA HCV Assay
6
Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras
8
Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA A,B,C, and intercellular adhesion 1 molecules Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
10
Expression of core antigen of HCV genotype 3a and its evaluation as screening agent for HCV infection in Pakistan
7
Consensus siRNA for inhibition of HCV genotype 4 replication
9
HCV genotype specific correlation with serum markers: Higher predictability for genotype 4a
9
Necessity for Reassessment of Patients with Serogroup 2 Hepatitis C Virus (HCV) and Undetectable Serum HCV RNA
5
Hepatic steatosis in HIV HCV coinfected patients receiving antiretroviral therapy is associated with HCV related factors but not antiretrovirals
10
ISG56 and IFITM1 Proteins Inhibit Hepatitis C Virus Replication
9
A variant in the CD209 promoter is associated with the severity of liver disease in chronic Hepatitis C virus infection
18
Detection of Anti Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System
6
Role of HCV Core gene of genotype 1a and 3a and host gene Cox 2 in HCV induced pathogenesis
13
NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
19
Investigating the Origin and Spread of Hepatitis C Virus Genotype 5a
7
Determination of hepatitis C virus genotypes in the United States by cleavase fragment length polymorphism analysis
7
HCV Antibody Response and Genotype Distribution in Different Areas and Races of China
7
Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials
21